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Abstract:  While we may be on the verge of a very exciting sci-tech era, many 
millions of people will fail to benefit from advances, just as millions already fail to 
reap the benefits of recent and not-so-recent developments in medical practices. An 
example of such an under-experienced innovation is organ and tissue transplantation, 
a field in which demand far exceeds supply in every country in the world. This is not 
because transplant techniques are particularly new, risky, or experimental. On the 
contrary, they are well understood and becoming routinised. This paper examines the 
social and cultural factors surrounding the recent implementation of a new legal 
regime governing transplantation in China. In particular, it considers how far this 
model can or could address a perennial problem associated with new and emerging 
(health) technologies, namely equitable access. Currently, very few people benefit 
from our understanding of, and growing capabilities in, organ and tissue 
transplantation (as well as other health advances). The paper then considers actions 
which ought to be taken to improve transplant medicine in China and beyond; actions 
which could improve public medicine dramatically. 
 
INTRODUCTION 
 
It is perhaps obvious that we are at the very fringes—the leading edge—of a sci-tech era that 
will be dominated by high technology solutions to social and technical problems, with 
implications of global, regional, local, and personal scales. A host of disciplines, including 
physics, engineering, and biology, are experiencing rapid evolutions, particularly the latter, 
which now contains sub-disciplines with genetic, engineering, synthetic, and nano-scale 
elements. What is less obvious, however, is whether much of humanity will benefit from 
these advances. While all manner of experimental medical innovations are pushing the 
boundaries of our preventative and curative capacities, many are expensive and imperfect; 
not at all ready to enter over-burdened or newly developed public healthcare systems. More 
troubling is that processes and procedures which are not experimental, but which are rather 
demonstrably effective, are not at all being deployed to maximum benefit. One such process 
is organ and tissue transplantation, or at least transplantation of certain organs and tissue. 
Obviously, success rates vary depending on the nature of the transplantation, and 
transplantations are often complex surgeries with concomitant risks, but the challenges are 
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generally well understood and can often be managed. Progress in medical science, surgical 
techniques, immunosuppressant drugs, and post-operative care since the first organ 
transplantation in 1954 (a kidney transplant between twin brothers) have mainstreamed 
transplantation in many health systems, making it reasonably routine and reliable.1 The first 
Chinese transplantation took place in 1969. Practices improved dramatically through the 
1980s and ‘90s. Hearts, lungs, livers, kidneys, pancreases, bones, skin and corneas are all 
now capable of transplantation in China, most with reasonably good 1-year and 5-year post-
operative patient survival rates.2 And the development of one of the largest transplantation 
programmes in the world together with recent national debates and reforms in China have 
encouraged greater ties with the international transplantation community, and China is 
expecting to benefit from this circumstance.3 
Nonetheless, despite existing capabilities, the majority of people who could benefit 
from (if not be cured by) transplantation languish under the burden of their conditions, and 
die. For example, 1-1.5 million Chinese patients require transplantations annually, but only 
11,000-13,000 transplantations are conducted.4 Over 100,000 patients suffer kidney failure 
annually, but only some 2,000 kidneys are available.5 Approximately 5 million patients suffer 
from blindness, of which some 30,000 would benefit from corneal transplantation, but only 
1,200 sight-restorative corneal transplantations are performed annually.6 In short, there is a 
huge deficit between supply and demand of organs and tissue suitable for transplantation. 
While some small portion of this deficit can be attributed to organ/tissue waste and export, 
most of it is the result of an ongoing inability to procure sufficient quantities (ie untapped 
capacity). This deficit, which is reproduced in virtually all countries around the world,7 
constitutes one of the most pressing problems facing China today, at least from a healthcare 
perspective for, as should be obvious from the above, a fully realised transplantation 
programme could improve the health and functionality of millions of people, with numerous 
knock-on effects. 
This paper examines transplantation in China. While stem cell research, particularly 
embryonic stem cell research, may facilitate the development of personalised regenerative 
medicine and thereby eventually transform transplantation practices and programmes, this is 
unlikely to happen anytime soon. Thus, more traditional (conventional) practices will have to 
satisfy public health needs. As such, this paper focuses on the transplantation of whole organs 
(eg kidneys, livers, etc.). First, it explores the unique social context that is China, identifying 
the particular social and institutional character that is exposed, and suggesting how that 
interacts with, or is relevant to, the medical transplantation context. Second, it examines 
China’s existing legal and ethical regulatory framework, evaluating how the institutions and 
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practices erected are responding to China’s needs, identifying major regulatory themes and 
gaps, and, importantly, articulating the values claimed and exposed. Third, drawing on these 
values, it offers an alternative framework for meeting China’s organ and human tissue needs, 
focusing on the key issues of oversight, procurement, and allocation. It concludes by offering 
some comments on how this ‘Chinese’ approach might be exported to other jurisdictions. 
 
THE SOCIAL CONTEXT: INSTITUTIONAL AND ATTITUDINAL TRANSITION 
AND AMBIVALENCE 
 
China’s Uneven Socio-Economic Development and its Interaction with Health 
 
China is a unique jurisdiction which straddles the ancient and the modern, the developing and 
the developed, the planned and the mixed/market. The current Chinese social context is 
characterised by rapid growth and transformation in a variety of sectors, including the 
academic,8 economic,9 and scientific sectors,10 and by stasis and fragmentation in other 
sectors, most notably the healthcare sector.11 Indeed, many key sectors, including the 
healthcare sector, are viewed merely as a means of supporting economic achievement by 
enhancing productivity and social stability.12 Thus, the economic transformation (and the 
economic agenda) colours all others and cannot be ignored. 
China has increased its development and production of goods, expanded external 
trade, initiated numerous overseas projects, and attracted significant foreign direct 
investment, realising an average annual GDP growth rate of 9.7%, and a 2005 trade surplus 
of some US$102 billion.13 It has invested substantial sums in high-tech and biotech R&D, 
recently climbing to third largest spender on R&D (with stem cell research considered a 
leading field).14 Moreover, it has maintained some public control of innovation through 
targeted spending (eg the 863 Plan,15 the 973 Plan,16 and others) and public sector 
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involvement in the commercialisation of outputs.17 Such integrated strategies have 
contributed to Chinese companies becoming much more innovative and competitive (eg one 
such company became the first to obtain a licence for a recombinant gene therapy directed at 
head and neck cancer).18 
Although this economic blossoming has had some positive impacts on healthcare,19 a 
similarly robust and positive transformation has not been realised in the health sector. The 
Chinese healthcare system is fragmented, under-funded, and responding poorly/slowly to 
China’s modernising efforts, which, as noted above, are creating pace and dynamism in other 
sectors.20 Healthcare responsibility has largely devolved to the provinces, financing is 
decentralised to the lowest administrative level, and although healthcare spending has 
increased dramatically, under-investment continues, and public spending is outweighed by 
out-of-pocket spending (eg the latter constitutes 54%-60% of all healthcare spending).21 
There exist immense disparities in access to services between regions and economic strata, 
the different health insurance systems which exist for rural and urban populations are not 
integrated, and the system suffers from severe understaffing and a low level of quality-of-
service-related regulation (eg ethics training is not yet the norm and many genetic practices 
have not yet undergone ethical-legal assessments).22 Recent attempts to reduce spiralling 
costs, provide more community-based services and universal insurance coverage, and to 
focus on preventive medicine have been mostly unsuccessful.23 
This fragile and unsettled system must address problems common to most developing 
countries (eg malnutrition, poor neonatal care, and inadequate immunisation against 
communicable diseases), while simultaneously responding to issues thrown up by rapid 
economic and social development, namely increasingly sedentary lifestyles (which lead to 
obesity and lifestyle related ailments), increasingly migratory/mobile populations (which 
increase the spread of communicable disease), and longer life expectancy (which increases 
the incidence and duration of non-communicable and chronic conditions such as heart 
disease, renal failure, cancer, and partial disability).24 Addressing these problems is made all 
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the more difficult by the widely dispersed and massive population the system has to serve (eg 
1.307 billion people over 9.6 million km2).25 
What of transplantation within this system? As noted above, there are millions of 
Chinese patients suffering from conditions which would benefit from transplantation. 
Recognising this, local (institution-based) transplantation programmes expanded 
dramatically. However, central policymakers failed to take a guiding hand in this expansion, 
thereby neglecting to provide any unifying regulatory framework. As such, as with other 
elements of Chinese healthcare, transplantation practices, effectiveness, and availability all 
evolved very unevenly, not least because of physician apathy and the unavailability of ICUs, 
or, alternatively, the inability of ICUs to respond adequately to prevailing conditions and 
opportunities.26 The result of this was (and continues to be) immense disparities in access to 
organs/tissue, deficiencies in clinical practice (ie quality of treatment and follow-up), 
widespread infringement of patient (donor) rights, the formation of an organ (black) market, 
and the growth of transplantation tourism (which prejudices Chinese patients).27 Thus, 
despite the expansion in transplantation programmes, and the notional ready availability of 
organs (due to a vast population base), demand in China far outstripped supply, and continues 
to do so. Given this growing access gap, transplantation programmes began to rely on 
executed prisoners, including minors, as a source for most of the transplanted organs, which 
approach brought Chinese transplant medicine under intense international scrutiny and 
criticism.28  
 
China’s Evolving Value Position on Transplantation 
 
As can be seen from the above, the existing Chinese organ/tissue deficit is the result of a 
variety of intertwined factors, all of which negatively impact on a core element of transplant 
medicine, namely procurement (ie: the effectiveness of supply-side activities). However, the 
above institutional and professional shortcomings are not the only impediments to improving 
transplant medicine in China. A further important aspect is that of public perceptions of, and 
attitudes toward, transplantation as a medical practice. Given our concern with values, it is 
important to explore in greater detail Chinese attitudes toward transplantation, an endeavour 
admittedly hampered by the relative lack of good evidence. Having said this, some evidence 
does exist and is supportive of some preliminary observations. 
In a 1990 survey of 2,000 subjects in Hong Kong, 53% of respondents were 
personally willing to be cadaveric donors (7% expressed unwillingness), and 39% were 
willing to donate family members’ organs (with 25% unwilling).29 A 2005 review of all 
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Hong Kong surveys conducted from 1990-2004 showed a trend toward a growing willingness 
to donate, combined with a reluctance to make donation decisions on behalf of family 
members.30 A 2005 survey of donor families in Hong Kong suggested that families were 
often ambivalent, confused, and under stress at the time of decision, and that they desired 
both informational support (regarding cause of death, meaning of brain death, funeral 
arrangements and financial assistance), and emotional support (a good/safe decision-making 
environment with access to health professionals and potential follow-up).31 In a 2006 survey 
of 434 university students in mainland China, 49.8% of the subjects were willing to be living 
donors (mostly for the benefit of family members), and 58.4% felt live donation would ease 
the organ shortage.32 
All of these surveys, with their evidence of a willingness to donate, expose a 
commonly shared value of concern for, or ‘solidarity’ with, other humans; certainly family 
members, but also other vulnerable people or groups. This generalised concern for the 
wellbeing of others is supported by the Confucian concept of ren, which means loving people 
and caring for others, and it supports ethical imperatives to care for patients. It is an extension 
of the natural compassion that everyone feels (or should feel) toward others in view of the 
hardships and misfortunes of those others,33 and it is in compliance with the ‘noble values of 
respect … and mutual help’ espoused by the State Council.34 Another value concept 
supported by the surveys is that of ‘reward for altruism’. For example, 48% of the 
respondents to the 2006 survey felt that partial compensation would effectively increase 
donor rates, and preferred this approach over purely voluntary or market based approaches.35 
In short, there was little affinity with purely altruistic donation, particularly for strangers, in 
part because the existing altruism-based system was viewed as having failed and therefore 
being inadequate. The increasing resonance of this value in Asia is not only demonstrated by 
the scholarship committed to it, but also by supportive statements from the Southeast Asian 
Bioethics Society, which accepted it as ethical where informed consent was present, coercion 
absent, donor care sufficient, third-party profiteers avoided, and fair compensation agreed.36 
Given the absence of any additional risk to donors, and of any evidence that such an approach 
would hinder (currently insufficient) cadaveric donation, some form of altruism-enhancing 
reward/compensation approach may be widely accepted.37 
Of course, as both the ongoing organ shortage and low donation rates (as compared to 
claimed willingness rates) demonstrate, there are also important countervailing phenomena.  
One is level of ambiguity (and therefore uncertainty) around the appropriate definition of 
death.  In particular, there is resistance to the reliance on brain stem death (as opposed to 
death measured by circulatory and respiratory cessation), particularly amongst certain 
religious groups.38  A second countervailing phenomenon, a more expressly value-based one, 
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and one which is exposed by the surveys, is a deep respect for the physical integrity of the 
deceased person, or ‘sanctification of the body’. The surveys highlight the continuing 
importance of traditional beliefs about rebirth; long enduring ideas about being reborn and 
therefore having to protect the integrity of the body make some people reluctant to be living 
or cadaveric donors and even more reluctant to make donation decisions on behalf of 
cherished family members (ie there is a reluctance to permit the removal of anything from the 
body lest it be missing upon rebirth).39 Although often unarticulated, this belief is present and 
becomes more prevalent in times of crisis and loss.40 Thus, while it has been challenged as 
inappropriate insofar as none of the major religions in Asia (Buddhism, Hinduism, Islam, 
Christianity) exhibit any hostility toward organ donation in the abstract,41 and while it is 
somewhat contrary to the Confucian approach to personhood—personhood is said to begin at 
birth, endure in those with capacity for social relations, and end at death42—this 
sanctification position continues to influence people’s conduct. Having said that, it does 
appear to be trending down as a decisive factor.43 
This very brief and admittedly unsophisticated consideration of the social context 
underlying transplantation in China suggests that China (collectively and individually) is in a 
state of transition on many fronts, with concomitant value shifts (and conflicts). While a great 
variety (and complexity) of personal values and motivations will be relevant to making 
personal decisions about organ donation for oneself or one’s family members, the evidence 
reviewed suggests that the values of (1) solidarity, (2) rewarded altruism, and (3) sanctified 
body/corpse integrity are widely shared. Their interaction (or rather competition), together 
with the foibles of, and burdens on, the existing healthcare system, have resulted in China 
experiencing a massive gap between demand and supply of organs and tissue, with the result 
that patients are deprived of life extension, and improved quality of existence, all of which 
have a concomitant knock-on effect for social wellbeing, healthcare costs, and productivity. 
How have legislators responded? 
 
THE REGULATORY RESPONSE: REACTIONARY AND COUNTER-
PRODUCTIVE LEGISLATIVE INSTRUMENTS 
 
China’s Belated and Future Regulatory Responses 
 
In the last decade, China has passed a variety of biomedicine regulations.44 Those most 
relevant to transplantation are the Regulation on Clinical Applications of Human Organ 
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Transplantation Technologies 2006 (Clinical Application Regulations),45 and the Human 
Organ Transplantation Ordinance 2007 (HOTO).46 The Clinical Application Regulations 
were the first transplant-related legal instrument in China. Always intended to be interim, 
they required transplantation institutions to register with the Ministry of Health, which would 
only certify them if certain scientific and ethical standards were met. They stipulated that 
every case should be submitted to an ethics committee for review and approval, and prior 
consent of both donors and recipients must be written and preceded by information. 
Additionally, organ trading was prohibited, a direct response to the international outcry over 
past practices (eg: transplantation tourism and organ procurement from prisoners). 
The HOTO is both more recent and more comprehensive than the Clinical 
Application Regulations. Intended to promote health, ensure quality healthcare, and 
safeguard the rights and interests of patients,47 it is directed at whole or partial organ 
transplantation (as opposed to cell, tissue, marrow or corneal transplantation, or cellular 
therapies).48 First and foremost, the HOTO bans the sale of organs and related activities,49 
reiterating that donation should be unpaid, voluntary and not induced or coerced.50 Prior 
written consent must be obtained from both donor (or the family of a deceased donor) and the 
recipient, and living donors must be over 18 years-old and must be a member of the 
recipient’s family.51 Medical institutions which conduct transplantations must register with 
the provincial health administration and meet certain qualifications relating to equipment, 
management practices, and ethical oversight.52 Unregistered institutions are prohibited from 
performing transplantations and qualified transplant physicians are not permitted to practice 
in unregistered hospitals.53 Every transplantation operation must be preceded by an 
Institutional Review Board review.54 Violations of the HOTO constitute a crime which could 
result in confiscation of derived income, fines and license revocation for institutions, and 
fines, transplant license revocation, and professional sanctions (including expulsion from the 
profession) for individuals.55 
Unfortunately, the HOTO, as it presently exists, suffers from a number of 
shortcomings, not least those relating to the availability of infrastructure to enforce it (and 
indeed the political will to do so).56 Political and healthcare system capacity concerns aside, 
the HOTO fails utterly to note (or to apparently take heed of) the reality of an ever-widening 
gap between supply and demand of tissue and organs for transplantation. Of particular 
importance to this situation, there is very little engagement with eligibility to be a donor; the 
definition of death and specification of eligibility can dramatically expand or shrink the 
potential donor pool. This is problematic given the Chinese ambiguity around the acceptance 
of brain death (and the concomitant advocacy from some corners of cessation of circulation 
                                                          
45  Decree No. 94 (2006), Ministry of Health, in force 1 July 2006. 
46  Decree No. 491 (2007), State Council, in force 1 May, 2007. 
47  Article 1, HOTO. 
48  Article 2, HOTO. 
49  Article 3, HOTO. Article 26 makes such conduct a crime and stipulates penalties. 
50  Article 7, HOTO. 
51  See Articles 8, 9 and 10, HOTO. This condition has caused a number of controversies where willing non-
related patients have wanted to exchange organs: see Xinhuanet, ‘Kidney Transplants Expose Regulation 
Holes’, China Economic Net, 13 January 2008, available at 
http://en.ce.cn/National/Local/200801/13/t20080113_14208052.shtml [accessed 22 october 2009]. 
52  See Article 11-15, HOTO. Additionally, such registration will be cancelled if certain success and survival 
rates are not met: see Article 17, HOTO. 
53  See Articles 11 and 13, HOTO. 
54  Article 11, 17 and 18, HOTO. 
55  Articles 25-31, HOTO. 
56  Y. Wang, supra, note 33. 
and respiration as the standard for death).57 Additionally, very little is said about organ 
procurement; aside from references to the need for informed consent and voluntariness, and 
for living donation to be aimed at someone in close relational proximity, donation is not 
regulated in detail. In particular, there is no direct prohibition of the use of prisoners, or, 
alternatively, clarification of how and under what circumstances organs might be obtained 
from prisoners, and this might have been warranted given the (troubled) history of their use, 
their ongoing use, and their particular institutional setting. 
In short, the HOTO might fairly be characterised as a reactionary response to an 
international outcry which is wholly inadequate to address the medical/social/moral problems 
to which it is directed; while it addresses the very important issue of clinical standards, it fails 
to address (or improve) other key issues, including public education, physician education, 
procurement enhancement, etc. Indeed, it has been reported that the HOTO has had the 
unenviable consequence of decreasing the number of cadaveric transplants by more than two 
or three fold, as well as reducing the number of institutions approved for performing 
transplants.58  
It has recently been reported that China is planning to revise its governance of 
transplantation to bring it more in line with international standards.59 As such, and in 
anticipation of this, one should highlight the WHO Guiding Principles on Human Cell, Tissue 
and Organ Transplantation (‘WHO Guiding Principles’),60 which state as follows: 
 
• Organs may be removed from the bodies of deceased persons for the purpose of 
transplantation if (a) any consent required by law is obtained, and (b) there is no 
reason to believe that the deceased person objected to such removal, in the absence of 
any formal consent given during the person’s lifetime.61 
 
• Physicians determining the death of a donor should not be directly involved in organ 
removal, transplantation, or care of the recipient(s).62 
 
• Cadaveric donation should be developed to its maximum potential, but adult living 
donors (not minors) are also acceptable, though they should be genetically related to 
recipients, and must give informed, voluntary consent.63 
 
• Organs should be donated altruistically and without monetary payment other than 
reimbursement of reasonable and verifiable expenses, and the offering, advertising, 
brokering, or purchasing of organs should be banned.64 
 
• If physicians or other carers have concerns about exploitation, coercion, or payment, 
they should refuse to perform the transplantation, and neither they nor their institution 
should receive payments exceeding a justifiable fee for services.65 
 
                                                          
57  Z. Liu et al., supra, note 3. 
58  J. Huang, Y. Mao & J Millis, supra, note 27. 
59  Ibid.  
60  Document EB123/5, WHO Executive Board, 26 May 2008. 
61  Principle 1. 
62  Principle 2. 
63  Principles 3 and 4. 
64  Principles 5 and 6. 
65  Principles 7 and 8. 
• Organs should be allocated according to clinical criteria and ethical norms, not 
financial or other considerations, and rules should be equitable and transparent.66 
 
• Monitoring, recording and oversight are necessary to protect quality, safety and 
efficacy, and management systems must be transparent and open to scrutiny while 
ensuring personal anonymity and privacy of donors and recipients.67 
 
These WHO Guiding Principals were revised in 2008 due, in part, to concerns over organ 
trafficking, with which China was deeply implicated, and it is anticipated that they will serve 
as a model for reforms. In fact, their previous manifestation served as a reference point for 
the HOTO, and it has been noted that such international guidelines are the result of 
communication and negotiation among experts from countries and cultures from around the 
world, including China, and should therefore be complied with, having reference to the 
cultural context when implementing them.68 
 
China’s Legislatively-Advanced Value Concepts 
 
As with the social setting, it is important to consider at least briefly the value concepts 
exposed by both the domestic and international regulatory instruments. What core values are 
exposed by the HOTO and the WHO Guiding Principles? And are they compatible with those 
suggested by the social setting? 
Foremost, are concerns for collective and individual patient ‘safety’ through multiple 
references to performance, facility and equipment standards, and to effective management 
systems. Additionally, ‘autonomy’, or respect for individual choice, is advanced through 
demands for the informed consent of both donors and recipients. Both instruments espouse 
‘altruism’ via directions that donors be unpaid. And, finally, ‘equity’ is advanced as 
important, at least in the WHO Guiding Principles, through references to allocation according 
to clinical indications and ethical norms. While these values do not mirror those evidenced in 
the social setting more broadly, they are by no means incompatible.  
Some further relevant values or concepts might be derived for the Chinese context 
from select provisions of the Constitution of the People’s Republic of China (Constitution),69 
which specifically tasks the state with promoting ‘high ideals’ and ‘ethics’.70 All of the 
myriad provisions which structure the socialist system harken to a belief in ‘social solidarity’ 
characterised by mutual respect, mutual reliance, and harmony.71 This concept of solidarity is 
bolstered by the entrenchment of a state duty to provide universal health services and welfare 
support.72 There is also some foundation for ‘equality’ as a moral/social value in references 
to everyone being equal under the law and under the socialist dictatorship, and to all 
nationalities within China being equal.73 There is a rhetorical affinity for ‘autonomy’ in 
provisions which extend freedom of political action, speech, religion, and privacy, which 
erect the inviolability of physical integrity, and which permit the pursuit of scientific and 
                                                          
66  Principle 9. 
67  Principles 10 and 11. 
68  X. Zhai & R. Qiu, supra, note 42. 
69  Adopted at the 5th Session of the Fifth National People’s Council, 4 December 1982, amended 1988 and 
1993, available at http://www.hkhrm.org.hk/english/law/const01.html [accessed 29 July 2009]. 
70  Article 24, Constitution. 
71  Chapter I, Constitution. 
72  Articles 21, 44 and 45, Constitution. 
73  Articles 1, 2, 4, 33 and 48, Constitution. 
creative endeavours.74 Finally, there is also a strong recognition of ‘duties’ on the part of the 
individual toward others and toward the state.75 
This assessment of the key legal instruments relevant to transplantation serves 
primarily to emphasise that legal responses in China have been late and inadequate, 
particularly with respect to improving organ and tissue supply, networking actors, and 
ultimately helping patients desperate for effective care and thereby alleviating healthcare 
system burden. It also highlights the value concepts that underlie these instruments, and the 
Chinese legal and social system more generally. It makes clear that existing regulatory efforts 
have not engaged particularly well with (ie have not clearly recognised and effectively 
advanced) the social values apparently relevant to the transplantation setting, nor indeed 
some of the broader values contained in the Constitution. 
We suggest that legislators must more effectively and creatively link social values, 
Constitutional values, and regulatory responses to particular medical problems, finding those 
areas of value convergence and adopting policy positions that vindicate those values while 
solving the particular (medical) problem to be addressed. Obviously, this represents an 
impressive but not insurmountable policy-making challenge. Our analysis, which relies on 
only preliminary social evidence, suggests that future reform of the Chinese approach to 
transplantation should have some regard to, and should advance where possible, concepts of 
(1) safety, (2) solidarity and altruism, (3) equity/equality, (4) autonomy, and (5) duty-
fulfilment. 
What might such a regime look like? 
 
THE FUTURE: POSSIBILITIES FOR A MORE EFFECTIVE TRANSPLANTATION 
REGIME 
 
All told we might highlight several primary reasons for the shortage of organs and tissue in 
China: (1) the general size of the population and the volume of demand it creates; (2) a 
traditional cultural antagonism toward division of the body; and (3) the complete inadequacy 
of the existing policy and regulatory framework to reverse organ deficit trends and promote 
greater commitment to donation. Focusing on the latter condition—the policy and regulatory 
framework—the remainder of this paper explores some reform possibilities aimed at 
increasing organ and tissue transplantation and improving transplantation management, 
bearing in mind the above driving values. 
At the outset, we note that the framing of the issue is of great importance. We start 
from the premise that transplantation, as a proven and cost-effective treatment option where it 
has been sufficiently developed,76 is (or should be) a favoured healthcare response to a 
variety of chronic and otherwise terminal conditions. Used maximally, it could improve the 
health, functionality, productivity, and enjoyment of life of millions of people, both in China 
and beyond, and in doing so, could have a transformative effect on healthcare delivery and 
healthcare system efficiency. One might characterise the chronic shortage of transplantable 
                                                          
74  Articles 33, 34, 35, 36, 37, 39, 40, 41, 47, Constitution. Note that, from a practice perspective, this 
autonomy—this decision-making space-creation—is less purely individualistic than that to which we are 
accustomed to claiming in the West; but family and community-influenced decision-making liberty is 
clearly espoused. 
75  Articles 33, 42, 46, 49, 51, 52, 53, 54, 55, 56, Constitution. 
76  Numerous studies have demonstrated that kidney transplantation is cheaper than, and improves longevity 
over, dialysis, as is the case with other forms of transplantation, such as liver and heart: see W. 
Winkelmayer et al., ‘Health Economic Evaluations: The Special Case of End-Stage Renal Disease 
Treatment’ (2002) 22 Med Decision Making 417-430, R. Adam et al., ‘Evolution of Liver Transplantation 
in Europe’ (2003) 9 Liver Transplant 1231-1243, D. Taylor et al., ‘2006 Report of the International Society 
for Heart and Lung Transplantation’ (2006) 25 J Heart Lung transplant 869-879, and others. 
organs and tissue as a purely social problem, but we prefer to characterise it as an acute moral 
issue; an unethical and unjust state of affairs that represents a fatal shortcoming of the 
healthcare system as it currently exists.77 By framing the issue as a pressing moral matter, 
one strengthens the imperative to remedy it, and expands the range of possible (defensible) 
mechanisms for doing so, the ultimate aim being to promote human wellbeing and advance 
human dao, which lies in ‘a good beginning and a good end’.78 
First, we reiterate that it is advisable that a comprehensive legislative framework be 
adopted. The benefits of this include the erection of enforceable boundaries, the provision of 
concept clarity for transplantation actors, the potential creation of greater public 
understanding and acceptance of transplantation, and satisfaction that all actors are operating 
within considered bounds. In addition to addressing risk, safety, and good clinical practice, it 
must positively define key terms (based on sound medical evidence). In particular, it must 
define ‘living donor’, outlining the circumstances under which organs/tissue might be taken 
from conscious individuals, including minors and those in state custody. It must define ‘brain 
dead donor’, offering a clear, practical and internationally accepted definition of brain death. 
And less controversially, it must define ‘non-heart-beating donor’. Like the present law, it 
should also address technical standards relating to the facilities and equipment used, 
providing for institutional application for transplant eligibility, site inspections, certification, 
and review/oversight. Finally, it should also stipulate standards for primary and support staff, 
erecting a licensing process comparable to that relating to institutions. 
We now turn to more specific oversight, procurement, and allocation issues. The 
solutions offered are grounded on our weighing of three factors: (1) the recognition of a 
moral imperative to improve public health through greater access to, and improved 
effectiveness of, transplant medicine in China; (2) the desire to advance some of the values 
(as we understand them) relevant to the transplant setting, particularly solidarity, rewarded 
altruism, safety, equity, and autonomy (in diminishing order of importance); and (3) the 
consideration of approaches that have proven effective in other jurisdictions (and which 
might not be completely anathema in China). It is our belief that the more comprehensive 
regime offered below would better vindicate the values relevant to this setting. 
 
Oversight 
 
A national Transplant Coordination Service (TCS), organised into central, regional and 
local/institutional branches, should be created so that trained and motivated transplantation 
experts could manage and advance transplantation medicine in China. The central/national 
Secretariat would (1) serve as the interface between the national government and the 
transplantation community, (2) set broad/national transplantation policy (including 
conducting public engagement exercises), and (3) erect and keep current national technical 
standards (through the hosting of expert consensus conferences). The regional branches 
would liaise with provincial governments and hospitals, and would additionally serve as the 
oversight arm of the TCS, certifying professionals as eligible transplant practitioners, 
licensing hospitals as transplant institutions, and recertifying their status through site and 
records inspections. They would audit institutions and practitioners for compliance with 
ethical allocation practices and generally ensure compliance with the statutory scheme. When 
breaches are alleged, either through independent inspections or patient complaints, they 
would investigate and determine whether to recommend prosecution. The local/institutional 
                                                          
77  Its moral foundation has also been recognized by others: see F. Cantarovich, ‘Reducing the Organ Shortage 
by Education and by Fostering a Sense of Social Responsibility’ (2003) 35 Transplantation Proceedings 
1153-1155. 
78  Xun Zi, 313-238 BCE. For more on Xun Zi, see http://www.iep.utm.edu/x/xunzi.htm. 
element of the TCS would comprise individual Transplant Coordinators; physicians and 
nurses acting on a part-time basis outside of their medical duties and reporting to their 
respective regional branches.79 A TCS would go a long way toward educating and obtaining 
evidence from the public, thereby permitting better, evidence-based policies in the future. 
Through its monitoring and enforcement of transplant standards, it would enhance patient 
safety, a value already explicitly considered of vital importance. It would also make 
transplant medicine more transparent and responsive, and therefore more democratic. 
 
Procurement 
 
Procurement, if it is to be effective, is a complex and costly undertaking. However, given 
China’s stated desire to improve healthcare and further economic development, it is a cost 
worth bearing and will, in the long term, save significant healthcare yuan. We suggest that if 
the Chinese transplantation programme hopes to close the gap between supply and demand 
(and perhaps one day meet demand),80 it must adopt an integrated, multi-pronged approach to 
organ/tissue procurement which includes: (1) an intense healthcare professional education 
programme for all physicians and nurses; (2) a concerted and ongoing public education and 
promotional campaign; (3) the formation of a national transplant coordination service; (4) a 
national opt-out policy for cadaveric donation; and (5) a rewarded donation system for living 
donations. 
 
Healthcare Professional Education: As noted above, there appears to be a certain level of 
ambivalence amongst healthcare professionals with respect to transplantation. Some of this 
may stem from traditional beliefs, but much of it probably stems from a poor or incomplete 
understanding of the costs, benefits, risks, and long-term consequences of transplantation for 
patients and for public health more generally, as well as on a general lack of technical support 
to effectively facilitate transplantations in the clinical setting. In addition to an increased 
focus on transplantation as a part of general medical education, all practicing physicians and 
nurses, especially those working in ICUs, Emergency Units, and Palliative Care Units,81 
should undergo mandatory continuing professional development training (in person and 
virtual/online) relating to transplantation. In addition to being informed about the value of 
transplantation and its importance to public health and national goals, training should focus 
on donor identification (which must occur early), donor screening (so disease transmission or 
infection are minimised), donor maintenance (so that organs are obtained in a usable state), 
sensitive physician-patient/family interaction (so a facilitative environment is created and 
information can be better shared and assimilated), and organ retrieval (best practices for 
removing, handling, preserving/storing, and transporting organs). 
 
                                                          
79  Parenthetically, the formation of an institution expert in transplantation matters would, presumably, 
enhance China’s ability to tackle the social, ethical and technical issues raised by xenotransplantation if and 
when it becomes a more viable healthcare option. 
80  It has been claimed that, at least in some jurisdictions, there appear to be sufficient deaths under suitable 
circumstances to satisfy annual organ demand if collection rates are adequate: K. Obermann, ‘Some 
Politico-Economic Aspects of Organ Shortage in Transplant Medicine’ (1997) 46 Soc. Sci. Med. 299-311. 
81  For more on the value of ‘marginal donors’ like the elderly, minors, diabetics, those with ischemia or 
infection, and so on, see G. Abouna, ‘Organ Shortage Crisis: Problems and Possible Solutions’ (2008) 40 
Transplantation Proceedings 34-38. 
Public Education/Promotion: Multi-media public education and promotional campaigns, 
both national and regional,82 should be undertaken on an ongoing or rolling basis. A general 
campaign, realised through print, radio, television, and web media, should advance the 
following concepts and messages:83 
 
• every individual bears duties grounded in solidarity and altruism to others in society 
and to the state; 
 
• duties extend to obligations to contribute to personal and public health and to the 
wellbeing of others, thereby improving national productivity; 
 
• transplantation is an important and integral part of effective modern healthcare and is 
contrary neither to any major religion, nor to traditional ethics; 
 
• every member of society is a potential donor and recipient (ie appeals to enlightened 
self-interest might highlight that the sharing of a personal resource, either during their 
life or after death or both, that is unique, may also benefit them in their lives); 
 
• clinical and social outcomes consequent to successful transplantations are typically 
favourable (and specific evidence might be provided); 
 
• the state and medical institutions are concerned with patient and public health, and 
risks to participants will always be minimised through strict safety measures and 
oversight. 
 
This general campaign should be supplemented by campaigns targeting specific audiences. In 
particular, young people should be reached and encouraged so that health solidarity and 
transplantation/donation may become a part of the national social fabric. 
 
Transplant Coordination Service: The TCS would take part in the proposed professional 
education and public promotion campaigns, bringing its unique perspective and evidence to 
bear, and it might also provide a 24-hour transplantation telephone hotline for those seeking 
information.84 Its activities would expand the number of facilities capable of undertaking 
transplantations, and it could thereby facilitate (and coordinate) equitable organ sharing 
between institutions. At the hospital level, individual Transplant Coordinators, rather than 
treating physicians or nurses, could continuously monitor potential donors and approach 
patients and families about donation and transplantation.85 They could provide information to 
individuals, assist in patient identification, articulate and resolve potential conflicts between 
being a patient and a potential donor, obtain consent (where applicable), coordinate the 
various actors involved in performing transplantations, and ensure the provision of adequate 
follow-up to both recipient and donor (if living) or family (if cadaveric). 
 
                                                          
82  Such a 2-tiered approach is necessary so that nuances in local character and local reasons for suboptimal 
donation can be addressed, whether they are sociocultural, religious, or otherwise: see S. Rizvi et al., supra, 
note 26. 
83  See T. Chan, supra, note 2, F. Cantarovich, supra, note 77, and others. 
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‘Strategies to Optimize Deceased Organ Donation’ (2007) 21 Transplantation Reviews 177-188. 
85  It has been reported that the Hong Kong Transplant Coordination Service, established in 1988, has enjoyed 
great success, raising the procurement rate from 10% to 40%: T. Chan, supra, note 2. 
Opt-Out System (Cadaveric Donation): A nation-wide opt-out system for cadaveric donation 
should be instituted whereby every member of society is automatically a contributor to 
transplant medicine.86 Thus, unless one specifically opts-out via a written form provided to a 
TCS coordinator and entered onto a central registry maintained by the TCS, one is 
automatically a member of the donation scheme such that when one dies, either naturally or 
by an accident, any organs and tissue of suitable quality are made available to patients within 
that region. Those who opt out would be issued an opt-out card to be carried on their person. 
Such an approach, when integrated with the other proposed actions, should dramatically 
increase organ and tissue availability, as has occurred in Spain.87 From a value perspective, 
this approach recognises the greater social embeddedness that individuals in China have as 
compared to those in many Western states; individuals typically maintain closer ties with 
family and/or community such that, in the medical context, families (and sometimes 
communities) are involved in the process of giving consent, and families often provide 
essential care and emotional and financial support.88 
While some will obviously complain that an opt-out approach diminishes, or is 
incompatible with, autonomy, we argue that it rather preserves autonomy and respect for the 
person insofar as every individual has the right, at any time, and after the consideration of as 
much or as little information as desired, to make an ‘informed choice’, to express that choice, 
and to have both respected. Ultimately, it strikes a reasonable balance between individual 
choice and promotion of the public good.89 It is impossible to say who might object to an opt-
out approach. This is an area which demands greater empirical work in China. But an opt-out 
approach would certainly have to overcome the traditional ‘sanctified bodily integrity’ value 
outlined above. Doing so would be one responsibility of the public education/promotion 
campaigns, but there is clear precedent of old beliefs being reinterpreted in response to new 
technologies, and ample support for this as an appropriate cultural and ethical undertaking. 
For example, it has been argued that filial piety must not be interpreted in a fundamentalist 
manner; it must be interpreted in keeping with xiao (to love, respect and care for parents) and 
ren (to love and care for and do good to others), which, in the modern context, support 
practices such as transplantation which are directed at treatment, and which outweigh old 
approaches to bodily integrity.90 
 
Rewarded Donation System (Living Donation): It is fair to characterise live organ/tissue 
donation as an intimate form of social interaction which should result in some form of 
                                                          
86  This is also sometimes called a ‘presumed consent’ approach. We prefer not to use ‘presumed consent’ 
because this is an unhelpful fiction; we are not presuming consent, we are disposing of the need for consent, 
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withdrawal. 
87  We caution that an opt-out approach alone is unlikely to substantially increase organ procurement rates: see 
H. Low et al., ‘Impact of New Legislation on Presumed Consent on Organ Donation on Liver transplant in 
Singapore: A Preliminary Analysis’ (2006) 82 Transplantation 1234-1237, A. Rithalia et al., ‘Impact of 
Presumed Consent for Organ Donation on Donation Rates: A Systematic Review’ (2009) 338 BMJ a3162, 
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Zhai & R. Qiu, ‘Biological Information of the Informed Consent of the Treasury Issue’ (2009) 10(2) 
Chinese Medical Ethics, available at http://translate.google.co.uk/translate?hl=en&sl=zh-
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n%26sa%3DN%26start%3D10 [accessed 30 July 2009]. 
90  See R. Qiu, ‘The Tension Between Biomedical Technology and Confucian Values’ in J. Tao (ed.), Cross-
Cultural Perspectives on the (Im)Possibility of Global Bioethics (Dordrecht: Kluwer, 2002) 71-88. 
reciprocity.91 In short, some benefits should be enjoyed by all participants (eg the public, the 
recipient, and the donor), and this seems to be the most fair and equitable approach (much 
more so than purely altruistic donation, which has proven wholly incapable of meeting 
demand).92 While it has been claimed that the near universal rejection of a commercialised 
organ trade is gradually eroding,93 it remains a controversial and, to many, an unpalatable 
option for increasing procurement rates.94 As such—and given the existing Chinese (and 
international) rejection of organ markets,95 as well as our touchstones of duty, solidarity, and 
rewarded altruism—a non-market approach to living donation is favoured. The survey 
evidence suggests that some recognition is warranted. This recognition could come in several 
forms, some of them compensatory, and it might include the following: 
 
• Social Recognition: While one might hope for donation decisions to be purely 
solidaristic, it is not necessary to demand unbridled altruism of people, and its 
absence need not taint the act. Recognition might take several forms, from letters of 
appreciation from government and/or recipient (anonymised or not), to certificates of 
special recognition from the government and/or health authorities, to inclusion on a 
publicly searchable national list of live donors (for those wishing to waive their 
privacy rights). 
 
• Enhanced Organ/Tissue Eligibility: Live donors, or a designated member of their 
immediate family, might automatically become eligible for ‘enhanced consideration’ 
should they develop a need for a transplantable organ or tissue. Their particulars could 
be entered onto national and regional registries until such time as they might have to 
enter a waiting list for a specific transplant, at which time they would be ranked as if 
they had been entered on the date of their donation. 
 
• Improved Health Insurance Coverage: Live donors, or a designated member of their 
immediate family, might automatically become eligible for improved health 
insurance, a reward which could have great significance in China, where health 
insurance coverage is unevenly enjoyed and where many healthcare costs are born by 
patients out-of-pocket. 
 
• Related Expenses: Live donors should receive financial compensation in the form of 
paid travel (and, if necessary, hotel) expenses for pre-op testing and post-op follow-up 
visits to the hospital, paid nutrition allowances for days spent travelling, wage 
continuation coverage for the duration of their convalescence, and a nominal, 
legislatively set financial award for the pain and inconvenience they will suffer as a 
result of surgery. This compensation might be contributed to by the state and by the 
private insurers of employers and hospitals. 
                                                          
91  This appears to be the position in Europe: M. Schweda & S. Schicktanz, ‘Public Ideas and Values 
Concerning the Commercialization of organ Donation in Four European Countries’ (2008) 68 Soc. Sci. 
Med. 1129-1136. 
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93  M. Schweda & S. Schicktanz, supra, note 91. Iran permits organ sales: see A. Daar, ‘The Case for a 
Regulated System of Living Kidney Sales’ (2006) 2 Nature Clin. Nephrology 600-601. And see C. Erin & 
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94  See these studies: M. Schweda & S. Schicktanz, ibid, and C. Mehmet et al., ‘How to Improve Organ 
Donation: Results of the ISHLT/FACT Poll’ (2003) 22 J Heart Lung Transplant 389-410. 
95  See Article 3, HOTO, and Principles 5 and 6, WHO Guiding Principles. 
 
This multiple reward system, built into the law, could reverse trends with respect to 
availability of quality transplantable organs from living donors (which are inarguably the best 
organs and the most likely to result in successful and long term health outcomes).96 
 
Allocation 
 
Aside from cases where a live donor’s organ is donated to a specified patient, donated organs 
(whether from living doors or cadavers) are properly classified as ‘public goods’ over which 
the community has authority and control, not the donor, the physician, or the hospital.97 This 
makes allocation a public concern. Where public knowledge and confidence exists with 
respect to allocation criteria and practices, procurement from both living and cadaveric 
donors might be enhanced; certainly the opposite—dissatisfaction with practices—can lead to 
diminished public support and reluctance to donate.98 Procurement enhancement aside, 
allocation is a key site for the realisation of social justice and the practical operation of 
medical ethics. As such, allocation must be addressed in the legislative framework, both 
generally, through the articulation of broad guiding values such as fairness and equality, and 
specifically through the enumeration of acceptable decision-making criteria. 
While allocation decisions must be seen as just/fair and equitable, perceptions of what 
constitutes justice and equity may shift over time. Thus, the statutory criteria—or ‘decisional 
factors’—should be ranked by the TCS, in cooperation with the medical community, and 
fashioned into an ethically defensible and practical decision-making tool which is made 
public. Some relevant criteria include: 
 
• histocompatibility; 
• demonstrated past lifestyle; 
• age of patient; 
• duration patient has been on the national waiting list; 
• existing quality of life of patient and life expectancy absent transplantation; 
• urgency of need; 
• anticipated quality of life and life expectancy post transplantation.99 
 
Each criterion should be given a narrow range of potential scores so that clinical cases can be 
compared and decisions justified (to the individual and the public).100 With some minor 
adjustments to rank and weight, these factors are relevant to most transplantable tissue. Thus, 
these criteria, regularly revisited, together with the maintenance of regional and national 
waiting lists, and agreed principles around a national organ sharing scheme (so that regions 
                                                          
96  See G. Abouna et al., ‘The Living Unrelated Donor: A Viable Alternative for Renal Transplantation’ (1988) 
20 Transplantation Proceedings 802-804, and more. 
97  And such has been widely accepted for some time: see J. Childress, ‘Ethics and the Allocation of Organs 
for Transplantation’ (1996) 6 Kennedy Inst Ethics J 397-401. 
98  See T. Koch, ‘Normative and Prescriptive Criteria: The Efficacy of Organ Transplantation Allocation 
Protocols’ (1996) 17 Theoretical Medicine 75-93. 
99  We recognise that this is a controversial factor, and that choosing between patients is a complex endeavour, 
which we do not have the space to explore here. Suffice to say that, it goes on all the time, and it is 
advisable to offer rules for such ranking decisions. 
100  Past cases of perceived inequity in the allocation decisions (in the west) have demonstrated that the public 
cares about such matters, and recent studies have shown that people are prepared to engage with difficult 
ethical questions in the transplant allocation context: see J. Stahl et al., ‘Balancing Urgency, Age and 
Quality of Life in Organ Allocation Decisions – What Would You Do? A Survey’ (2008) 34 J Med Ethics 
109-115. 
that might have acted competitively might better cooperate to the betterment of ethical 
outcomes and for the greater good), might significantly advance transplant medicine in 
China. 
 
Summary 
 
First, while we have focused on the legislative element, we have envisioned a legislative 
regime that supports a variety of mechanisms—some administrative, some educational, and 
some legal—to achieve the desired end. It is a joined-up approach structured by a legislative 
scheme, and implicating the criminal law, but only peripherally. Second, while it faces some 
challenges in the Chinese cultural context, the fluidity of that context must be recognised, and 
in particular the decline of practices/beliefs which might be explicitly resistant to the regime 
offered. Third, while the cost of such a scheme would not be negligible, we believe it would, 
in the long run, be more cost-efficient than many current non-transplantation-based options. 
Further, it is more readily available in that it does not rely on the (future) perfection of 
expensive high biotechnologies that are still in the developmental phase (eg stem cell 
therapies). As for how the costs of the scheme would be met, that is a political question 
incapable of being addressed in the present work. Finally, while one would hope the system 
would reach all corners of China, geography is a problem; it might have to develop in the 
more financially secure and culturally cosmopolitan east, and spread from there. 
 
CONCLUSION 
 
Conditions resulting in organ degradation and failure (and concomitant transplantation needs) 
are serious burdens on public health systems, on families, and indeed on ailing patients, in 
China and elsewhere. In many cases, transplantation represents the best treatment with 
respect to functionality, productivity, and cost-efficiency. As such, while transplantation is 
not a ‘cheap’ component of healthcare, it should be a key pillar of modern healthcare 
responses in China and elsewhere; transplants need to be more widely available, more 
quickly obtainable, and more confidently/safely receivable. 
The integrated regime sketched out above can meet these needs. Importantly, it relies 
on, and advances, values that are either clearly embedded or widely claimed in China.101 One 
obvious victim is the traditionally grounded sanctification of the body, but this value is both 
widely lamented and diminishing in relevance, and so might properly be transitioned out of 
the public conscience via the public education and promotional campaigns. Further empirical 
research is needed with respect to opinions and attitudes toward donation and transplant 
governance in (mainland) China, as well as the state of xenotransplantation and artificial 
organ transplantation, and social acceptance of same. Armed with such evidence, the system 
can be further tweaked to better reflect Chinese ideals. 
While this regime was fashioned with a view to the Chinese context, we believe that 
many elements of the offering are transferable to other jurisdictions, including Western ones. 
Although the solidarity value and the idea of duties are not as strongly felt in the West, we 
note that Western welfare systems are grounded on solidarity, and that there is a growing call 
for the better articulation and realisation of duties in health and other contexts. In any event, 
the recognition of a broader base of values in Western countries may serve to increase the 
positive response to transplantation by diverse communities within such countries (eg 
                                                          
101  It is important to note that we do not erect and deploy the values identified in a principlist manner. We are 
not suggesting that they should or must inform all Chinese medical decisions. Rather, we believe there is 
evidence that these broad values exist and we have drawn on them where we think appropriate in support of 
a regime we believe would advance healthcare. 
Canada, the UK and US all have large Chinese and other immigrant communities which 
might respond favourably to a regime which better or more explicitly draws on values 
resonant in those communities).102 In short, we do not see the value-base of this scheme as 
being a great hindrance to exportation, and we suggest that exportation of at least core 
elements is important to promoting international harmonisation (if not standardisation), and 
therefore broadly improving transplant medicine outcomes. 
As a parting comment, we must stipulate that the key to the successful improvement 
of transplant medicine in China and elsewhere is the adoption of an integrated and multi-
pronged approach; partial responses will likely result in little net improvement. The ultimate 
objective, whether in China or beyond, should be to realise the Confucian ideal of xiaokang, 
the ‘well-off society’. 
 
 
                                                          
102  We suggest that one avenue for improving response rates in such communities is to generate more and 
better evidence of the value positions and practices within those communities, both in the host country and 
the country of origin. 
